pipette
ESEspañol

A highly potent bispecific antibody confers complete protection against SFTSV in preclinical models

Xiaoping Guo, Fujian Wan, Wujian Li, Qing‐Cui Zou, Entao Li, Weiqi Wang, Fangxu Li, Zunhao Zhou, Xiaoman Yang, Qiyuan Yang, Xinyu Wang, Xiang Gao, Haoyi He, Wenyu Xie, Aiqing Hou, Yanan Su, Hongliang He, Min-Yu Li, Bo Shu, Sandra Chiu

Peer-reviewed journalClaims a big stepReal-world use

In the authors' words

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging bunyavirus that causes severe human disease, with a case fatality rate of up to 30%. However, no licensed therapeutics are currently available for clinical use. Here, we identified two SFTSV neutralizing nanobodies (Nbs), N2C1 and N2D2, which inhibited both viral attachment and membrane fusion. Structural analysis revealed that N2C1 spanned Gn domain I and domain III, while N2D2 targeted domain I, located at the inner and outer sides of the Gn–Gc hexamer crown, respectively. They also exhibited synergistic neutralization, and their bispecific antibody (bsAb) displayed dramatically enhanced neutralizing potency. In a lethal mouse model, the bsAb demonstrated superior protective efficacy over the parental Nbs in both preexposure and postexposure administration regimens. More importantly, in preclinical ferret models, the bsAb N2D2-Fc-N2C1 conferred complete protection against SFTSV not only at a low dose of 5 mg/kg but also when administered as late as 2 d postinfection. These results demonstrate the potent protective efficacy of N2D2-Fc-N2C1, supporting its development as a promising clinical candidate against SFTSV infection.

Main resultThe abstract does not state a limitation.

In plain words AI summary

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging bunyavirus that can kill up to 30% of infected people, and no approved treatments exist. The researchers found two nanobodies, N2C1 and N2D2, that block SFTSV by stopping both viral attachment and membrane fusion. Structural analysis showed N2C1 spans two domains of the viral protein, while N2D2 targets one domain, and together they work synergistically. A bispecific antibody combining both nanobodies showed dramatically enhanced neutralizing potency and superior protection in mice compared to the individual nanobodies. In ferrets, the bispecific antibody N2D2-Fc-N2C1 gave complete protection at just 5 mg/kg, even when given two days after infection.

Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.

Appeared: Friday, October 2. Proceedings of the National Academy of Sciences. Peer-reviewed journal.

DOI: 10.1073/pnas.2613799123